New drug duo aims to tame Hard-to-Treat blood cancer

NCT ID NCT06645678

First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 17 times

Summary

This study tests whether combining two medicines, mezigdomide and elranatamab, can shrink tumors or slow disease in people with multiple myeloma that has come back or stopped responding to other treatments. About 75 adults will take part. The goal is to see how many patients achieve at least a partial response, and how long they stay progression-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center, University of Ulsan College of Medicine

    RECRUITING

    Seoul, South Korea

  • Chonnam National University Hwasun Hospital

    RECRUITING

    Hwasun, South Korea

  • National University Hospital (NUH)

    RECRUITING

    Singapore, Singapore

    Contact

  • Samsung Medical Center, Sungkyunkwan University School of Medicine

    RECRUITING

    Seoul, South Korea

  • Seoul National University Hospital

    NOT_YET_RECRUITING

    Seoul, South Korea

  • Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea

    RECRUITING

    Seoul, South Korea

  • Singhealth Duke NUS blood cancer center

    RECRUITING

    Singapore, Singapore

    Contact

Conditions

Explore the condition pages connected to this study.